Sofosbuvir-Velpatasvir

• Hepatitis C Virus Infection
• Chronic HCV All Genotypes
• HCV with Cirrhosis

Sofosbuvir-velpatasvir (Epclusa) is a once-daily, fixed-dose combination direct-acting antiviral (DAA) that achieves sustained virologic response — effectively a cure — in over 95% of patients with chronic hepatitis C across all six major HCV genotypes. Its pangenotypic activity has simplified treatment selection enormously and made HCV eradication realistic on a population scale. Treatment is now considered a routine part of primary care in many practices, no longer the exclusive domain of hepatology specialists, and the WHO has set a goal of eliminating HCV as a public health threat by 2030 — a goal that depends on widespread access to regimens like this one.

Mechanism of Action

The combination targets two essential nonstructural HCV proteins. Sofosbuvir is a uridine nucleotide analog prodrug that, after intracellular triphosphorylation, is incorporated into the nascent viral RNA strand by the NS5B RNA-dependent RNA polymerase. Once incorporated, it acts as a chain terminator and halts viral replication. Velpatasvir binds the NS5A protein, a multifunctional component required for viral RNA replication, virion assembly, and release from infected hepatocytes.

Attacking two essential, mechanistically distinct viral proteins creates a high genetic barrier to resistance. Resistance-associated substitutions (RAS) in NS5A — particularly Y93H — can blunt response in some genotype 3 patients with cirrhosis, settings where adding ribavirin or extending duration may be appropriate. Routine baseline RAS testing is not required but is sometimes performed in difficult cases. The HCV Guidelines maintained jointly by AASLD and the Infectious Diseases Society of America are the definitive treatment reference and are updated frequently as evidence accumulates.

Because sofosbuvir is a uridine analog, its primary clearance is renal; this matters less in the general population but did historically complicate dosing in advanced kidney disease — though current data support use even in end-stage renal disease on dialysis. Velpatasvir is hepatically cleared and does not accumulate in renal failure. The host immune response, particularly innate interferon signaling, contributes to clearance of residual viral reservoirs once direct-acting antiviral pressure has reduced viral replication below the threshold for sustained productive infection.

Clinical Use

Sofosbuvir-velpatasvir is approved for adults and pediatric patients aged 3 and older with chronic HCV genotypes 1 through 6. It is given for 12 weeks in patients without cirrhosis or with compensated cirrhosis (Child-Pugh A). For decompensated cirrhosis (Child-Pugh B or C), the regimen is combined with weight-based ribavirin for 12 weeks. Treatment duration may be extended in selected difficult-to-treat populations such as genotype 3 with cirrhosis and prior treatment failure.

Alternative pangenotypic regimens include glecaprevir-pibrentasvir, an 8-week option in many treatment-naive patients without cirrhosis. Choice between regimens often comes down to comorbidities, drug interactions, prior treatment history, kidney function, and insurance formulary. For patients with prior DAA failure, the triple combination of sofosbuvir, velpatasvir, and voxilaprevir (Vosevi) is reserved as salvage therapy and typically achieves SVR even in those who have failed first-line DAA regimens.

Universal HCV screening is now recommended by the USPSTF and CDC for all adults at least once and during every pregnancy, given how readily curable the disease has become. Patients with chronic hepatitis — whether from HCV or other causes — benefit from coordinated care that addresses concurrent fatty liver disease, alcohol use, and metabolic factors. The article on alcohol health effects is essential context, as continued heavy alcohol use can blunt cure benefit through ongoing liver injury. Treatment of concurrent hepatitis B with entecavir or tenofovir may be needed to prevent reactivation during DAA therapy. For patients with concurrent HIV, antiretroviral therapy should be reviewed for interactions before starting DAAs, with bictegravir-emtricitabine-tenofovir, dolutegravir, and darunavir being common choices.

How to Take It

One tablet (sofosbuvir 400 mg / velpatasvir 100 mg) once daily, with or without food, at approximately the same time each day. Adherence is critical — even a few missed doses can compromise cure rates and select resistant virus. Use pill organizers, phone alarms, or directly observed therapy where appropriate. The 12-week course is short, which makes adherence more achievable than older interferon-based regimens that required months and produced miserable side effects. For patients with substance use comorbidity, supervision through methadone clinics or harm-reduction programs has demonstrated equally high cure rates and should not be a barrier to offering treatment.

Stomach acid significantly affects velpatasvir absorption. Antacids should be separated from the dose by at least 4 hours. H2-blockers such as famotidine may be taken simultaneously or 12 hours apart at doses up to famotidine 40 mg twice daily equivalent. Proton pump inhibitors should ideally be avoided; if necessary, use only a low dose (omeprazole 20 mg or equivalent — including pantoprazole, esomeprazole, rabeprazole, or dexlansoprazole) taken 4 hours before sofosbuvir-velpatasvir, and discuss alternatives with the prescriber such as as-needed antacids or short-term H2-blocker use during the 12-week treatment course. Many patients can tolerate a short pause from PPI therapy with substitution of famotidine or ranitidine alternatives during the limited treatment window.

If vomiting occurs more than 4 hours after a dose, no replacement dose is needed; if within 4 hours, take another dose. Counsel patients to maintain follow-up even after treatment ends — sustained virologic response is confirmed 12 weeks after the last dose (SVR12) and is the formal definition of cure. Re-infection is possible if exposure recurs, particularly through ongoing injection drug use; counseling and harm-reduction support remain important after cure.

Monitoring and Follow-Up

Before starting therapy, screen for hepatitis B virus with HBsAg, anti-HBs, and anti-HBc — HBV reactivation during HCV DAA therapy can cause hepatic failure and death (boxed warning). Patients with evidence of prior HBV exposure (anti-HBc positive even with negative HBsAg) need at minimum close monitoring of HBV DNA during therapy, and active HBV infection requires concurrent suppressive treatment. Obtain baseline HCV RNA, HCV genotype (or use a pangenotypic regimen and skip genotyping), CBC, comprehensive metabolic panel including LFTs, INR, and either FibroScan, APRI, FIB-4, or biopsy to assess fibrosis stage. Our understanding blood work article explains how LFTs and synthetic markers are interpreted in chronic liver disease.

During treatment, check LFTs at week 4 and at the end of treatment, with HCV RNA at end of treatment and 12 weeks after completion to confirm SVR12. Patients with cirrhosis remain at elevated risk for hepatocellular carcinoma even after cure and require ongoing surveillance with abdominal ultrasound and AFP every 6 months indefinitely. Vaccinate against hepatitis A and hepatitis B if not immune. Counseling on alcohol moderation or abstinence supports long-term liver health, and the article on how alcohol affects the body after 50 is a useful resource for older patients adjusting their drinking patterns post-cure.

Special Populations

No dose adjustment is needed for any degree of hepatic impairment, although ribavirin must be added for decompensated disease. No adjustment for mild-to-severe renal impairment, including end-stage renal disease on dialysis. Pediatric dosing is weight-based for children aged 3 and older, with oral pellets available for those who cannot swallow tablets.

The drug should not be used with strong P-gp inducers or moderate-to-strong CYP inducers — rifampin, carbamazepine, phenytoin, phenobarbital, and St. John's Wort all reduce drug levels enough to compromise cure. Coadministration with amiodarone has produced fatal symptomatic bradycardia and should be avoided when possible; if unavoidable, inpatient cardiac monitoring during initiation is required. Pregnancy data for sofosbuvir-velpatasvir alone are limited; ribavirin (when added) is teratogenic and pregnancy must be avoided in patients receiving ribavirin and their male partners during therapy and for 6 months after. Patients on chronic anticoagulants like warfarin need INR monitored more closely, and statin doses should be reviewed because of potential interactions.

When to Contact Your Doctor

Call promptly for: jaundice, dark urine, marked fatigue, or new abdominal swelling (consider HBV reactivation or worsening liver function); bradycardia or syncope (especially if amiodarone is involved); or a positive pregnancy test on ribavirin-containing therapy. Report any new prescription, over-the-counter, or supplement use during treatment for interaction screening — this includes seemingly benign products like antacids and herbal supplements. The MedlinePlus sofosbuvir-velpatasvir page and the FDA prescribing information are reliable references.

If you have questions about sofosbuvir-velpatasvir or your hepatitis C treatment plan, our team at Zimmer Medical Group can help — contact us or schedule a visit.